BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780)
South Korea · Delayed Price · Currency is KRW 3,480.00
-155.00 (-4.26%)
Jun 10, 2026, 3:30 PM KST
BCWORLD PHARM. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 79,812 | 75,800 | 74,814 | 75,111 | 72,703 | 62,079 |
Other Revenue | -0 | -0 | -0 | - | -0 | - |
| 79,812 | 75,800 | 74,814 | 75,111 | 72,703 | 62,079 | |
Revenue Growth (YoY) | 7.37% | 1.32% | -0.40% | 3.31% | 17.11% | 8.85% |
Cost of Revenue | 47,926 | 45,258 | 46,803 | 43,234 | 45,497 | 42,149 |
Gross Profit | 31,886 | 30,541 | 28,012 | 31,876 | 27,206 | 19,931 |
Selling, General & Admin | 16,999 | 17,895 | 15,945 | 16,127 | 21,261 | 11,662 |
Research & Development | 9,410 | 8,990 | 7,779 | 6,141 | 770.66 | 9,298 |
Amortization of Goodwill & Intangibles | 342.75 | 347.71 | 325.26 | 287.74 | 235.2 | 110.4 |
Other Operating Expenses | 325.64 | 319.57 | 302.2 | 132.24 | 58.84 | 200.34 |
Operating Expenses | 27,389 | 28,545 | 26,512 | 25,511 | 25,344 | 21,464 |
Operating Income | 4,498 | 1,997 | 1,500 | 6,365 | 1,862 | -1,534 |
Interest Expense | -4,117 | -4,239 | -4,760 | -5,234 | -3,792 | -2,169 |
Interest & Investment Income | 113.2 | 122.22 | 207.91 | 187.98 | 129.42 | 180.31 |
Currency Exchange Gain (Loss) | -13.42 | -59.97 | 54.35 | 110.63 | 376.05 | 317.28 |
Other Non Operating Income (Expenses) | 310.7 | 232.82 | 240.24 | -285.96 | 501.3 | 498.41 |
EBT Excluding Unusual Items | 791.06 | -1,948 | -2,758 | 1,144 | -923.13 | -2,707 |
Gain (Loss) on Sale of Investments | -139.92 | -126.41 | -28.94 | 13.42 | -535.17 | -229.14 |
Gain (Loss) on Sale of Assets | -104.51 | -137.7 | 20.77 | 48.91 | -0.32 | -0 |
Asset Writedown | - | - | - | - | -64.29 | - |
Pretax Income | 546.64 | -2,212 | -2,766 | 1,206 | -1,523 | -2,936 |
Income Tax Expense | 1,028 | 931.28 | 550.12 | -1,686 | -1,583 | 42.06 |
Earnings From Continuing Operations | -481.37 | -3,143 | -3,316 | 2,892 | 59.78 | -2,978 |
Minority Interest in Earnings | -2,028 | -1,754 | -1,116 | -258.52 | 221.52 | 1,135 |
Net Income | -2,510 | -4,897 | -4,433 | 2,634 | 281.3 | -1,843 |
Net Income to Common | -2,510 | -4,897 | -4,433 | 2,634 | 281.3 | -1,843 |
Net Income Growth | - | - | - | 836.31% | - | - |
Shares Outstanding (Basic) | 9 | 9 | 9 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 10 | 10 | 10 |
Shares Change (YoY) | -0.18% | 0.19% | -9.18% | -0.98% | -0.19% | 0.35% |
EPS (Basic) | -271.05 | -527.02 | -478.00 | 257.95 | 27.28 | -178.39 |
EPS (Diluted) | -271.05 | -527.02 | -478.00 | 257.95 | 27.28 | -178.39 |
EPS Growth | - | - | - | 845.59% | - | - |
Free Cash Flow | -2,687 | 1,589 | 1,644 | 8,361 | 666.21 | -18,064 |
Free Cash Flow Per Share | -290.18 | 171.04 | 177.33 | 818.82 | 64.61 | -1748.42 |
Gross Margin | 39.95% | 40.29% | 37.44% | 42.44% | 37.42% | 32.10% |
Operating Margin | 5.63% | 2.63% | 2.00% | 8.47% | 2.56% | -2.47% |
Profit Margin | -3.14% | -6.46% | -5.92% | 3.51% | 0.39% | -2.97% |
Free Cash Flow Margin | -3.37% | 2.10% | 2.20% | 11.13% | 0.92% | -29.10% |
EBITDA | 12,565 | 9,945 | 9,194 | 13,835 | 9,070 | 3,641 |
EBITDA Margin | 15.74% | 13.12% | 12.29% | 18.42% | 12.48% | 5.86% |
D&A For EBITDA | 8,068 | 7,949 | 7,694 | 7,470 | 7,208 | 5,174 |
EBIT | 4,498 | 1,997 | 1,500 | 6,365 | 1,862 | -1,534 |
EBIT Margin | 5.63% | 2.63% | 2.00% | 8.47% | 2.56% | -2.47% |
Effective Tax Rate | 188.06% | - | - | - | - | - |
Advertising Expenses | - | 1,333 | 922.8 | 1,274 | 1,505 | 1,085 |